Effect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia

Behavioural Brain Research

Volumn 222, Issue 2, 2011, Pages 299-308

  Gururajan, Anand ^a   Taylor, David Alan ^b   Malone, Daniel Thomas ^a  

^a MONASH UNIVERSITY   (Australia)

^b EASTERN HEALTH   (Australia)

Author keywords

Antipsychotic; Cannabidiol; Clozapine; MK 801; Schizophrenia

Indexed keywords

CANNABIDIOL; CLOZAPINE; DIZOCILPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RAT; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; STARTLE REFLEX; TRANQUILIZING ACTIVITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CANNABIDIOL; CLOZAPINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; DRUG INTERACTIONS; INHIBITION (PSYCHOLOGY); INTERPERSONAL RELATIONS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; STARTLE REACTION;

EID: 79955964765     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.03.053     Document Type: Article

References (58)

1. Adams R., Hunt M., Clark J.H. Structure of cannabidiol, a product isolated from the Marihuana extract of Minnesota wild hemp. I. J Am Chem Soc 1940, 62:196-200.
2. Gururajan A., Malone D.T., Taylor D.A. Advances in cannabidiol research as an antipsychotic. Curr Top Pharmacol 2009, 13:17-23.
3. Zuardi A.W., Crippa J.S., Hallak J.E.C., Moreira F.A., Guimaraes F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 2006, 39:421-429.
4. Long L.E., Malone D.T., Taylor D.A. The pharmacological actions of cannabidiol. Drugs Future 2005, 30:747-753.
5. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 2006, 26:365-384.
6. Stone J.M. Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des 2009, 15:2594-2602.
7. Wong E.H., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-d-aspartate antagonist. Proc Natl Acad Sci USA 1986, 83:7104-7108.
8. Rung J.P., Carlsson A., Ryden Markinhuhta K., Carlsson M.L. (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psych 2005, 29:827-832.
9. Ouagazzal A., Nieoullon A., Amalric M. Effects of dopamine D1 and D2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology (Berl) 1993, 111:427-434.
10. Gattaz W.F., Schummer B., Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect 1994, 96:227-232.
11. Gururajan A., Taylor D.A., Malone D.T. Effect of testing conditions on the propsychotic action of MK-801 on prepulse inhibition, social behaviour and locomotor activity. Physiol Behav 2010, 99:131-138.
12. Kilts C.D. The changing roles and targets for animal models of schizophrenia. Biol Psychiatry 2001, 50:845-855.
13. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 2001, 156:117-154.
14. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 1990, 47:181-188.
15. Weike A.I., Bauer U., Hamm A.O. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biol Psychiatry 2000, 47:61-70.
16. Braff D.L., Swerdlow N.R., Geyer M.A. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry 1999, 156:596-602.
17. Porsolt R.D., Moser P.C., Castagne V. Behavioral indices in antipsychotic drug discovery. J Pharmacol Exp Ther 2010, 333:632-638.
18. Castagne V., Moser P.C., Porsolt R.D. Preclinical behavioral models for predicting antipsychotic activity. Adv Pharmacol 2009, 57:381-418.
19. Gururajan A., Taylor D.A., Malone D.T. Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav Pharmacol 2010, 21:690-709.
20. Morimoto T., Hashimoto K., Yasumatsu H., Tanaka H., Fujimura M., Kuriyama M., et al. Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H-[1]benzothieno[2,3-b][1,5] benzodiazepine maleate). Neuropsychopharmacology 2002, 26:456-467.
21. Bubenikova V., Votava M., Horacek J., Palenicek T., Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol Biochem Behav 2005, 80:591-596.
22. Martin R.S., Secchi R.L., Sung E., Lemaire M., Bonhaus D.W., Hedley L.R., et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berl) 2003, 165:128-135.
23. Long L.E., Malone D.T., Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006, 31:795-803.
24. Long L.E. Neuropharmacological studies of the effect of cannabinoids on some behavioural and molecular correlates of psychosis 2006, Monash University, Melbourne.
25. Nespor A.A., Tizabi Y. Effects of nicotine on quinpirole- and dizocilpine (MK-801)-induced sensorimotor gating impairments in rats. Psychopharmacology (Berl) 2008, 200:403-411.
26. Snell L.D., Yi S.J., Johnson K.M. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol 1988, 145:223-226.
27. Tricklebank M.D., Singh L., Oles R.J., Preston C., Iversen S.D. The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 1989, 167:127-135.
28. Rao T.S., Kim H.S., Lehmann J., Martin L.L., Wood P.L. Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J Neurochem 1990, 54:1157-1162.
29. Zuo D.Y., Zhang Y.H., Cao Y., Wu C.F., Tanaka M., Wu Y.L. Effect of acute and chronic MK-801 administration on extracellular glutamate and ascorbic acid release in the prefrontal cortex of freely moving mice on line with open-field behavior. Life Sci 2006, 78:2172-2178.
30. Lopez-Gil X., Babot Z., Amargos-Bosch M., Sunol C., Artigas F., Adell A. Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007, 32:2087-2097.
31. Yan Q.S., Reith M.E., Jobe P.C., Dailey J.W. Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 1997, 765:149-158.
32. Loscher W., Annies R., Honack D. The N-methyl-d-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 1991, 128:191-194.
33. Hiramatsu M., Cho A.K., Nabeshima T. Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 1989, 166:359-366.
34. Wang Y.H., Bosy T.Z., Yasuda R.P., Grayson D.R., Vicini S., Pizzorusso T., et al. Characterization of NMDA receptor subunit-specific antibodies: distribution of NR2A and NR2B receptor subunits in rat brain and ontogenic profile in the cerebellum. J Neurochem 1995, 65:176-183.
35. Bresink I., Danysz W., Parsons C.G., Mutschler E. Different binding affinities of NMDA receptor channel blockers in various brain regions-indication of NMDA receptor heterogeneity. Neuropharmacology 1995, 34:533-540.
36. Kohr G. NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res 2006, 326:439-446.
37. Wenzel A., Scheurer L., Kunzi R., Fritschy J.M., Mohler H., Benke D. Distribution of NMDA receptor subunit proteins NR2A, 2B, 2C and 2D in rat brain. Neuroreport 1995, 7:45-48.
38. Swerdlow N.R., Braff D.L., Geyer M.A. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behav Pharmacol 2000, 11:185-204.
39. Long L.E., Chesworth R., Huang X.F., McGregor I.S., Arnold J.C., Karl T. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 2009, 1-16.
40. Hoffman D.C., Donovan H., Cassella J.V. The effects of haloperidol and clozapine on the disruption of sensorimotor gating induced by the noncompetitive glutamate antagonist MK-801. Psychopharmacology (Berl) 1993, 111:339-344.
41. Levin E.D., Caldwell D.P., Perraut C. Clozapine treatment reverses dizocilpine-induced deficits of pre-pulse inhibition of tactile startle response. Pharmacol Biochem Behav 2007, 86:597-605.
42. Swerdlow N.R., Keith V.A., Braff D.L., Geyer M.A. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 1991, 256:530-536.
43. Swerdlow N.R., Zisook D., Taaid N. Seroquel (ICI 204,636) restores prepulse inhibition of acoustic startle in apomorphine-treated rats: similarities to clozapine. Psychopharmacology (Berl) 1994, 114:675-678.
44. Bakshi V.P., Swerdlow N.R., Geyer M.A. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response. J Pharmacol Exp Ther 1994, 271:787-794.
45. Swerdlow N.R., Shoemaker J.M., Bongiovanni M.J., Neary A.C., Tochen L.S., Saint Marie R.L. Strain differences in the disruption of prepulse inhibition of startle after systemic and intra-accumbens amphetamine administration. Pharmacol Biochem Behav 2007, 87:1-10.
46. Moreira F.A., Guimaraes F.S. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005, 512:199-205.
47. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76:245-250.
48. Hoffman D.C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 1992, 89:1-10.
49. Mueller K. Locomotor stereotypy is produced by methylphenidate and amfonelic acid and reduced by haloperidol but not clozapine or thioridazine. Pharmacol Biochem Behav 1993, 45:71-76.
50. van Ree J.M., Niesink R.J., Nir I. delta 1-Tetrahydrocannabinol but not cannabidiol reduces contact and aggressive behavior of rats tested in dyadic encounters. Psychopharmacology (Berl) 1984, 84:561-565.
51. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., et al. Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995, 120:67-74.
52. Boulay D., Depoortere R., Louis C., Perrault G., Griebel G., Soubrie P. SSR 181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 2004, 46:1121-1129.
53. Becker A., Grecksch G. Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1267-1277.
54. Steinpreis R.E., Sokolowski J.D., Papanikolaou A., Salamone J.D. The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat. Pharmacol Biochem Behav 1994, 47:579-585.
55. Ahnaou A., Megens A.A., Drinkenburg W.H. The atypical antipsychotics risperidone, clozapine and olanzapine differ regarding their sedative potency in rats. Neuropsychobiology 2003, 48:47-54.
56. Bast T., Zhang W., Feldon J., White I.M. Effects of MK801 and neuroleptics on prepulse inhibition: re-examination in two strains of rats. Pharmacol Biochem Behav 2000, 67:647-658.
57. Meltzer H.Y., Matsubara S., Lee J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989, 251:238-246.
58. Narayanan S., Willins D., Dalia A., Wallace L., Uretsky N. Role of dopaminergic mechanisms in the stimulatory effects of MK-801 injected into the ventral tegmental area and the nucleus accumbens. Pharmacol Biochem Behav 1996, 54:565-573.